Jeffrey Hatfield, CEO, Director at Vitae Pharma, holds 293.90K shares in Vitae Pharma (Ticker: VTAE), holds ― shares in Invivo Therapeutics Holdings (Ticker: NVIVQ), holds ― shares in Viridian Therapeutics (Ticker: VRDN).
Jeffrey Hatfield latest transaction was an Uninformative Sell of $5.14M.
What was Jeffrey Hatfield's most profitable transaction?
Jeffrey Hatfield’s most profitable transaction was an Informative Buy of VTAE stock on January 26, 2015. The return on the trade was -32.90%.
What is Jeffrey Hatfield's role in Vitae Pharma?
Jeffrey Hatfield's role in Vitae Pharma is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.